Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PVLA vs ARQT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARQT Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

ARQT Overall Winner 6-Pillar Tally: PVLA 0 – 5 ARQT (1 Tie) Matrix Metrics: PVLA 2 – 8 ARQT

As of Nov 16, 2026, Arcutis Biotherapeutics, Inc. (ARQT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas ARQT carries 62.5/100 (BUY) at $27.19 (25.8x Forward P/E, 6.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PVLA vs ARQT
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 35.0 Fund 53.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.9 · SMA20: $148.17 · SMA50: $143.42
ARQT NASDAQ Head-to-Head Winner
Arcutis Biotherapeutics, Inc. Common Stock
Pharmaceutical Preparations
$27.19
-3.79% 1D
Market Cap $3.5B
TTM Revenue $509M
Forward P/E 25.8x
Beta / 30D Vol 1.76β · 87% Vol
Unified Composite Score
62.5 / 100 BUY
Tech 58.0 Fund 58.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $30.11 · SMA50: $27.61

6-Pillar Scorecard Institutional Category Breakdown (PVLA 0 – 5 ARQT)

Columns: Metric · PVLA · ARQT
1. Valuation Multiples ARQT
Forward P/E N/M 25.8x
Trailing P/E N/M 125.1x
PEG Ratio N/M N/M
EV / Revenue N/M 7.0x
2. Growth & Scale ARQT
Revenue Growth (YoY) +0.0% +45.1%
Earnings Growth (YoY) +0.0% +3.3%
TTM Revenue (USD) N/A $509M
Market Cap $2.2B $3.5B
3. Profitability & Quality ARQT
Gross Margin N/A 91.2%
Operating Margin 0.0% 6.9%
Net Profit Margin 0.0% 5.9%
Return on Equity (ROE) -63.4% 14.9%
4. Balance Sheet & Cash Flow ARQT
Cash Generation (TTM) -$43M $60M
Cash Flow Margin N/A 11.7%
Net Cash / Leverage $193M Net Cash $81M Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 47.9% (2nd %ile) 60.7% (7th %ile)
Put/Call OI Skew 3.82x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat ARQT
OpEx & R&D Intensity N/A 84.3% of Rev ($429M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PVLA (2) vs ARQT (8)
Institutional Metric PVLA ARQT Criterion Row Edge
Market Capitalization
Scale
$2.2B $3.5B Larger Scale ARQT
Trailing P/E Ratio
Valuation
N/M 125.1x Lower Multiple ARQT
Forward P/E Ratio
Valuation
N/M 25.8x Lower Multiple ARQT
Revenue Growth (YoY)
Growth
+0.0% +45.1% Higher Growth ARQT
Operating Margin (TTM)
Profitability
0.0% 6.9% Higher Margin ARQT
Net Profit Margin
Profitability
0.0% 5.9% Higher Margin ARQT
Return on Equity (ROE)
Capital Efficiency
-63.4% 14.9% Higher ROE ARQT
52-Week Range Position
Momentum
68% ($72–$180) 51% ($19–$35) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.66β · 75% Vol 1.76β · 87% Vol Lower Realized Risk PVLA
Unified Institutional Score
Composite Signal
48.2 / 100 (HOLD) 62.5 / 100 (BUY) Higher Composite ARQT
Trailing 12M Revenue (USD)
Operating Scale
N/A $509M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 91.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$43M ($193M Net Cash) $60M ($81M Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +26.22 pp
PVLA: +20.56% · ARQT: -5.66%
3M Horizon ARQT +6.03 pp
PVLA: -3.58% · ARQT: +2.45%
6M Horizon PVLA +2.31 pp
PVLA: +38.06% · ARQT: +35.75%
1Y Horizon PVLA +61.22 pp
PVLA: +80.16% · ARQT: +18.94%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PVLA Revenue ARQT Revenue PVLA Op. Margin ARQT Op. Margin Margin Leader
FY2018 $30M N/A -113.1% N/A PVLA
FY2019 $40M N/A -62.2% N/A PVLA
FY2020 $30M N/A -115.7% N/A PVLA
FY2021 $30M N/A -165.0% N/A PVLA
FY2022 $30M $0M -167.8% -8183.0% PVLA
FY2023 $40M $60M -27.7% -404.5% PVLA
FY2024 N/A $200M N/A -65.3% ARQT
FY2025 N/A $380M N/A -3.3% ARQT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARQT CONSOLIDATION
91d in phase · OBV ACCUMULATION
Current IV 60.7%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact ARQT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ARQT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.5B market capitalization and 6.9% operating margin.
OpEx & R&D Reinvestment 84.3% of Rev ($429M)
90D Engineering Disclosures 0 Published

Investor FAQ PVLA vs ARQT Key Questions & Quantitative Answers

As of Nov 16, 2026, Arcutis Biotherapeutics, Inc. (ARQT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas ARQT carries 62.5/100 (BUY) at $27.19 (25.8x Forward P/E, 6.9% operating margin). Technically, PVLA sits in a Neutral phase (RSI 50.9, CONSOLIDATION options structure) and ARQT sits in a Neutral phase (RSI 46.0, CONSOLIDATION options structure).

ARQT leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ARQT at +45.1% YoY revenue growth and +3.3% YoY earnings growth on $509M TTM revenue (91.2% gross margin, 6.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PVLA cumulative revenue shifted +33.3% while ARQT shifted +533.3%. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus 84.3% of Rev ($429M) (0 disclosures) for ARQT.

ARQT screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ARQT trades at 25.8x Forward P/E, 125.1x Trailing P/E, N/M PEG, and 7.0x EV/Revenue (11.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus ARQT (14.9% ROE) capital efficiency.

In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, ARQT carries 60.7% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.76β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.